A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives
Open accessThe DOI matches its Crossref record; 327 of the 327 references it cites were found in a registry or an index; 135 of the 655 sources its claims cite were checked for support.
Abstract
Type 2 diabetes (T2D), which has currently become a global pandemic, is a metabolic disease largely characterised by impaired insulin secretion and action. Significant progress has been made in understanding T2D aetiology and pathogenesis, which is discussed in this review. Extrapancreatic pathology is also summarised, which demonstrates the highly multifactorial nature of T2D. Glucagon-like peptide (GLP)-1 is an incretin hormone responsible for augmenting insulin secretion from pancreatic beta-cells during the postprandial period. Given that native GLP-1 has a very short half-life, GLP-1 mimetics with a much longer half-life have been developed, which are currently an effective treatment option for T2D by enhancing insulin secretion in patients. Interestingly, there is continual emerging evidence that these therapies alleviate some of the post-diagnosis complications of T2D. Additionally, these therapies have been shown to induce weight loss in patients, suggesting they could be an alternative to bariatric surgery, a procedure associated with numerous complications. Current GLP-1-based therapies all act as orthosteric agonists for the GLP-1 receptor (GLP-1R). Interestingly, it has emerged that GLP-1R also has allosteric binding sites and agonists have been developed for these sites to test their therapeutic potential. Recent studies have also demonstrated the potential of bi- and tri-agonists, which target multiple hormonal receptors including GLP-1R, to more effectively treat T2D. Improved understanding of T2D aetiology/pathogenesis, coupled with the further elucidation of both GLP-1 activity/targets and GLP-1R mechanisms of activation via different agonists, will likely provide better insight into the therapeutic potential of GLP-1-based therapies to treat T2D.
Overview
CoChat Summary
TL;DR
This narrative review summarizes type 2 diabetes epidemiology, multifactorial aetiology/pathogenesis, extrapancreatic complications, and treatments, with emphasis on GLP-1 receptor-based therapies. It argues that GLP-1R agonists, including emerging allosteric and multi-receptor agonists, may improve glycaemia, weight, and systemic complications, while many mechanistic uncertainties remain.
Key findings
- T2D is described as a global pandemic: ~382 million patients globally in 2013, projected >590 million by 2035 and >700 million by 2045; T2D accounts for ~90% of diabetes cases. Obesity is a major risk factor, reported to increase T2D risk by 90-fold, and genetic susceptibility is supported by ~70% monozygotic twin concordance, 40% lifetime risk with one affected parent, and almost 70% with both parents affected.
- Pathogenesis involves beta-cell dysfunction/apoptosis, peripheral insulin resistance, alpha-cell dysregulation, islet amyloid/IAPP deposition, and a diminished incretin effect, where GLP-1 and GIP account for <20% of insulin release after glucose ingestion in T2D. Extrapancreatic pathology includes cardiovascular disease, diabetic nephropathy, neuropathy, and NAFLD, reported in ~70% of T2D patients.
- GLP-1-based therapies are central: native GLP-1 has a half-life of 1–2 minutes, whereas exenatide has 3.4–4 hours and liraglutide 11–13 hours; GLP-1R agonists augment glucose-dependent insulin secretion, suppress glucagon, delay gastric emptying, and induce weight loss. In a 160-week liraglutide trial, T2D diagnosis occurred in 2% vs 6% of placebo-treated participants, and time to T2D onset was 2.7x longer with liraglutide.
- Emerging approaches include GLP-1R allosteric agonists (compounds 2 and B) and GLP-1/GIP/glucagon tri-agonists tested in rodents, which improved glycaemia, body weight, and islet architecture. Bariatric surgery can induce T2D remission—one study reported 53% complete remission at three years and another 10% partial remission—but carries complications such as vomiting/dumping syndrome, iron and B12 deficiency, and secondary hyperparathyroidism.
Methods
- Narrative review of published literature on T2D epidemiology, aetiology, pathogenesis, treatments, and future perspectives; no primary data collection or systematic search strategy is described.
- Synthesizes preclinical and clinical evidence, including rodent models, human islets, autopsy studies, and clinical trials; the main analysis is qualitative narrative synthesis.
Limitations
- The paper does not present a formal limitations section; limitations stated in the text include unresolved mechanisms, conflicting findings (e.g., glucolipotoxicity, UCP2, GIP action), uncertainty from undiagnosed diabetes in global prevalence estimates, and the caveat that animal-study observations may have limited clinical implications for humans.
- Evident from the text: as a narrative review, it lacks a described systematic search, inclusion criteria, or formal quality appraisal, and it relies on heterogeneous cited studies without meta-analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
87 Valid · 11 Not valid · 355 Not checked · 7 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“One study demonstrated the importance of genetics in T2D susceptibility independently of the diet as there was a higher prevalence of the disease in the twin population compared to the singleton population77”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Type 2 Diabetes > Aetiology
What the sources say
- Disputedcites [77] Poulsen, 2009, Diabetes sourceExperimental — accuracy not yet measured
The Discussion confirms that elderly twins had a higher prevalence of type 2 diabetes than singletons. But the Abstract’s Conclusions interpret the finding as evidence for a significant impact of the fetal environment “as opposed to genetics,” contrary to the claim that the comparison demonstrates the importance of genetics. These passages also do not establish independence from diet. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“It has been shown that a high proton motive force (PMF) results in the production of ROS, and as UCP2 activity can lower the PMF by increasing proton leak, it can then lower intracellular ROS, as well as increased production of ROS, is thought to be at least partly dependent on an increased mitochondrial PMF in islet beta-cells.180,183–185”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Type 2 Diabetes > Pathogenesis
What the sources say
- Supportedcites [180] Affourtit, 2011, Free Radic Biol Med source
The Discussion (‘UCP2 function and regulation’) says UCP2 contributes to mitochondrial proton leak. The Discussion (‘GSIS regulation by UCP2’) also describes UCP2 activity as partially dissipating mitochondrial membrane potential, supporting the claimed mechanism. (LLM, conf=0.92)
- Not checked yetcites [183] Pi, 2010, Diabetes Obes Metab source
- Disputedcites [184] Robson-Doucette, 2011, Diabetes sourceExperimental — accuracy not yet measured
The paper’s Results say UCP2 does not contribute to classical proton leak in β-cells, and its Discussion says the increased ROS observed after UCP2 deletion is not caused by reduced proton leak. Although the introduction acknowledges reports of UCP2-facilitated proton leak elsewhere, the paper’s findings contradict that mechanism in the islet β-cell context of the citing sentence. Page numbers are unavailable in our copy. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“TNFα secretion from T2D subjects was higher than healthy controls,207,208 and one in vitro study has shown that this myokine impairs beta-cell function.208”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Extrapancreatic Tissues Involvement in T2D: Aetiology/Pathogenesis and Post-Diagnosis Complications
What the sources say
- Supportedcites [207] Ciaraldi, 2016, PLoS One source
The Results/Discussion of our copy state that TNFa secretion is elevated in T2D myotubes relative to non-diabetic cells: Discussion (p. n/a) says 'Our current observation that TNFa secretion, while low, is elevated in T2D myotubes is confirmatory of our earlier results', and the Discussion also summarizes 'our results that secretion of TNFa, IL6 and MCP-1 are all elevated in T2D myotubes'. The Introduction frames the same comparison against cells from non-diabetic (ND) individuals. Note the parallel circulating TNFa difference in Table 2 was not retained after BMI adjustment, but the claim concerns secretion, which the paper supports. (LLM, conf=0.90)
- Disputedcites [208] Bouzakri, 2011, Diabetes sourceExperimental — accuracy not yet measured
Our copy contains no measurement of TNF-α secretion comparing type 2 diabetic subjects with healthy controls; the study is entirely in vitro, using human myotubes rendered insulin resistant by added TNF-α (RESULTS, 'Myokine expression and secretion from human skeletal muscle cells (myotubes) treated with or without TNF-α'). On the contrary point, the DISCUSSION states 'At present, there is little evidence for elevated TNF-α in the skeletal muscle of individuals with type 2 diabetes,' and the background passage (labeled Abstract > CONCLUSIONS in our copy) says the source of increased circulating TNF-α in type 2 diabetes 'remains unclear, but it does not appear to be the muscle itself (18),' with elevated levels in obesity/T2D credited to refs 18-19 rather than shown here. So the muscle-derived ('myokine') elevation the citing sentence attributes to this source is contradicted by our copy; only the separate in vitro β-cell/GSIS impairment finding (TNF-α in TM blunting GSIS, blocked by Ethanercept) is supported. (LLM, conf=0.68)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“There are a range of effective treatments that reduce hyperglycaemia in T2D patients, which mediate their effects by improving insulin secretion or decreasing peripheral tissue insulin resistance.8”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Introduction
What the sources say
- Supportedcites [8] Raz, 2013, Diabetes Care source
The paper’s sections on individual drug classes describe several effective glucose-lowering treatments with these mechanisms. The sulfonylureas and meglitinides section says they increase insulin secretion, while the PPAR-γ: pioglitazone section says that class lowers blood glucose by reducing insulin resistance and improving insulin sensitivity in muscle. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Better glycaemic control has been reported in T2D patients who have lost weight, and excess body weight is associated with the risk of cardiometabolic complications, which are major causes of morbidity and mortality in T2D and obese individuals.11,12”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Introduction
What the sources say
- Supportedcites [11] Horton, 2010, Diabetes Care source
The Conclusions report that weight loss was associated with better glycemic control in patients with type 2 diabetes. The Results (Regression analysis) specify that this benefit appeared with any weight loss in exenatide-treated patients, but only with weight loss of at least 8% in the sitagliptin and insulin groups. (LLM, conf=0.92)
- Supportedcites [12] Wilding, 2014, Int J Clin Pract source
The ‘Effects on glycaemic control’ section says that weight loss improves glycaemic control in people with T2DM and that those who lose weight are more likely to reach target HbA1c values. The ‘Message for the clinic’ and Introduction also link excess weight to cardiometabolic complications and cardiovascular risk. Page numbers are not available in our copy. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
212 more claims · 48 with their cited sources checked
Create a free account to see all 460 claims and to verify the 520 references still open.
- It may state two separate claims as one. 213
- Probably not a substantial claim. 60
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Emerging evidence supports the concept that deposition of ectopic fat within pancreatic islets, possibly inside β cells themselves, contributes to progressive impairment of β-cell function (which is reversible with weight loss)115 in individuals who are genetically susceptible.116–118”
From Definition and diagnostic criteria of clinical obesity (2025) · cites this paper as [116]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Type 2 Diabetes > Pathogenesis
“peripheral insulin resistance is a requisite precursor for the development of this disease.”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Type 2 Diabetes > Pathogenesis
“T2D has been shown to manifest in non-overweight individuals in the absence of insulin resistance, although this is thought to be rare.140”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Pharmacological Treatments and Lifestyle Changes for T2D
“exenatide has a half-life of 3.4–4 hours”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Pharmacological Treatments and Lifestyle Changes for T2D
“| Exenatide (Byetta) | Twice daily | 2.4 hours | Yes |”
Citations
Cites
1 retracted
Wang, M., Yao, P., Gao, M., Jin, J., & Yu, Y. (2020) · RSC Advances · doi:10.1039/c9ra10593j · Cited by 9
RetractedSaeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., Colagiuri, S., Guariguata, L., Motala, A. A., Ogurtsova, K., et al. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107843 · Cited by 10,792 · cited 6×
“estimated that there will be over 700 million T2D patients worldwide.(1,62) However, as highlighted in”
InfluentialBiochemistry and molecular cell biology of diabetic complications
Brownlee, M. (2001) · Nature · doi:10.1038/414813a · Cited by 9,107
The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Global estimates of the prevalence of diabetes for 2010 and 2030
Shaw, J. E., Sicree, R. A., & Zimmet, P. Z. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.10.007 · Cited by 7,216
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationGlobal estimates of diabetes prevalence for 2013 and projections for 2035
Guariguata, L., Whiting, D. R., Hambleton, I., Beagley, J., Linnenkamp, U., & Shaw, J. E. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.11.002 · Cited by 4,642
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Research works printed but not linked: 25
- Thompson, 2013, Clin Exp Pharmacol, 1, 3
- 2010, Clinical Problems Caused by Obesity
- 2012, The Disease Burden Associated with Overweight and Obesity
- Templeman, 2017, J Endocrinol, 2017, 58
- Hu, 2011, Role Diet Lifestyle Genes, 34, 1249
- 2011, Biochemistry
- Karalliedde, 2016, Nephrol Dialysis Transplant, 31, 206
- Ali, 2010, Indian J Med Res, 132, 584
- Mazzola, 2012, Am J Manag Care, 18, 17
- Saeedi, 2019, Diabetes Res Clin Pract, 2, 157
- 1985, Diabetes in America
- Hyttinen, 2003, Nationwide Follow Up Study, 52, 1052
- Torres, 2008, Gastroenterol Hepatol (N Y), 4, 568
- Wilcox, 2005, Clin Biochemist Rev, 26, 19
- Cnop, 2005, Many Differences Few Similarities, 54, S97
- Gerich, 2000, J Clin Endocrinol Metab, 85, 2113
- Ivan Quesada, 2008, J Endocrinol, 2, 68
- Shah, 2000, J Clin Endocrinol Metab, 85, 4053
- Clark, 1988, Diabetes Res, 9, 151
- Perry, 2016, Exerc Immunol Rev, 22, 94
- Keshel, 2015, J Obes Weight Loss Ther, 5, S5
- 2018, Encyclopedia of Signaling Molecules
- Halverson, 1986, Am Surg, 52, 594
- Avinoah, 1992, Surgery, 111, 137
- 2017, Encyclopedia of Signaling Molecules
Cited by
Items 201–300 of 442
Estrada, A. K., Méndez-Álvarez, D., Juárez-Saldívar, A., Lara-Ramirez, E. E., Martínez-Vázquez, A. V., Villalobos‐Rocha, J. C., Palos, I., Ortíz-Pérez, E., & Rivera, G. (2023) · Medicinal Chemistry · doi:10.2174/1573406419666230803122020 · Cited by 4
Pang, X., Bai, S., Feng, Z., Zhang, Y., Hu, B., & Zhang, Y. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s501318 · Cited by 4
“24 However, the phenotypes of commonly used T2DM rodent models, such as db/db mice and Zucker fatty rats, result from point mutations in the leptin receptor-encoding gene, not from the regulation of environmental factors.”
Yin, M., Zheng, H., Han, B., Wu, B., Qing, Y., Deng, H., Xu, K., Liu, H., Tao, M., Li, Y., et al. (2025) · Advanced Exercise and Health Science · doi:10.1016/j.aehs.2025.11.004 · Cited by 3
Houas, M., Benamor, M. L., Lanez, E., Bekkar, Y., Bourougaa, L., Boudebia, O., Bouraoui, R., Adaika, A., Zouaghi, N., Nacer, S. N., et al. (2026) · Chemistry & Biodiversity · doi:10.1002/cbdv.71277 · Cited by 3
Understanding Diabetes Remission
Velayutham, K., Panneerselvam, G., & Ramanathan, B. (2025) · Apollo Medicine · doi:10.1177/09760016251323727 · Cited by 4
“[3] The conventional therapeutic approach for T2D has focused on lifelong management, prioritising blood glucose control and reducing complications with the combination of medications and lifestyle changes.”
Meenu, M., Bano, U., Mujeeb, M., Akhtar, M., Aqil, M., Haque, S. E., & Najmi, A. K. (2025) · ACS Omega · doi:10.1021/acsomega.5c02026 · Cited by 4
The functioning of otolith organs in individuals with type-II diabetes mellitus
Kumar, P., Singh, N. K., Raveendran, R. K., Apeksha, K., Ghosh, P., & Bhanukumar, M. (2025) · Hearing Research · doi:10.1016/j.heares.2025.109412 · Cited by 3
Nwagwe, O. R., Adefegha, S. A., & Oboh, G. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.117562 · Cited by 3
Lee, M., Tariq, A. R., & Kim, M. (2024) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2024.101673 · Cited by 3
“Many available treatments improve insulin secretion but these treatments may cause hyper and hypoglycaemia [13], weight gain (sulfonylureas and meglitinidies) and gastrointestinal intolerance (metformin and alpha glucosidase inhibitors) [14].”
BackgroundAl-Qahtani, A. A. (2024) · Journal of General and Family Medicine · doi:10.1002/jgf2.659 · Cited by 11
Reed, J., Higginbotham, V., Bain, S. C., & Kanamarlapudi, V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126331 · Cited by 3
“Therefore, GLP-1-based therapies are a promising treatment option for the multifactorial disease T2D, given their potential to alleviate the systemic pathology associated with this disease via direct and indirect mechanisms [8–10].”
BackgroundSelf-citationNadeem, S., Maqbool, T., Qureshi, J. A., Altaf, A., Naz, S., Azhar, M. M., Ullah, I., Shah, T. A., Qamar, M. U., & Salamatullah, A. M. (2024) · Medicina · doi:10.3390/medicina60060961 · Cited by 3
“Diabetes mellitus has a complex pathogenesis [1].”
Hoekx, C. A., Straat, M. E., Bizino, M. B., van Eyk, H. J., Lamb, H. J., Smit, J. W. A., Jazet, I. M., de Jager, S. C. A., Boon, M. R., & Martínez‐Téllez, B. (2024) · Experimental Physiology · doi:10.1113/ep091815 · Cited by 3
Mousavi, A., Shojaei, S., Abhari, A. P., Mirhosseini, S. A., Ebrahimi, R., Rajabi, E., Farooqi, M. A., Azizpour, A., Moghadam, S. A., Kuno, T., et al. (2025) · American Journal of Hypertension · doi:10.1093/ajh/hpaf140 · Cited by 4
Dong, S., Yu, K., Tang, S.-H., Guo, J., Guo, Y., & Yang, T. (2022) · medRxiv · doi:10.1101/2022.12.16.22283558 · Cited by 3
García‐Guzmán, P., Aceves, L. S., Almanza, L. O., & Romero-Canto, P. (2024) · International Journal of Drug Delivery Technology · doi:10.25258/ijddt.14.1.07 · Cited by 2
Jawad, A. N., Kadhim, K. A., Alzajaji, Q. B., & Al-Neshmi, H. (2024) · Al Mustansiriyah Journal of Pharmaceutical Sciences · doi:10.32947/ajps.v24i3.1082 · Cited by 2
Pyridine Derivatives: A Comprehensive Review of Their Potential as Anti-Diabetic Agents
Dua, D., Kumar, P., Anand, R., Sood, S., & Singh, G. (2025) · Medicinal Chemistry · doi:10.2174/0115734064342827241230053148 · Cited by 2
Alamri, A. M. A., Althaqafi, A. S., Salawati, R., Asiri, R. M., Aldugman, M. A., Saleh, M., AlAsmari, B. A., Albraik, M. A., & Ghazy, R. M. (2025) · Medicine · doi:10.1097/md.0000000000044356 · Cited by 2
“[17] It 18–20] According to the International Diabetes Federation, approximately 10.5% of adults aged 20 to 79 years were living with diabetes in 2021, with this number projected to rise to 46% by 2045.”
InfluentialHentilä, J., Tuisku, J., Ojala, R., Sun, L., Lietzén, M. S., Virtanen, H., Läutamaki, R., Koskensalo, K., Nummenmaa, L., Löyttyniemi, E., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70109 · Cited by 2
Sukatta, U., Rugthaworn, P., Klinsukhon, K., Tumnark, P., Songcharern, N., Teethaisong, Y., Kanpetta, Y., & Phoemsapthawee, J. (2025) · Nutrients · doi:10.3390/nu17213358 · Cited by 2
Pang, X., Song, D., Huang, X., Zheng, Y., Sun, L., Meng, H., & Wu, H. (2025) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.70215 · Cited by 2
Regenerative medicine approaches for treating diabetes: Current advances and future directions
Medenica, S., Abazović, D., Vuković, J., Vojinović, T., Tomović, F., Defeudis, G., Mazzilli, R., Kovačević, Z., Djurdjic, D., Prelević, V., et al. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109232 · Cited by 5
A Pharmacovigilance Analysis of Ocular Adverse Events Associated with GLP-1 Receptor Agonists
Virk, A., & Allison, K. M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15062464 · Cited by 3
Diabetes and metabolic disorders: Early identification and monitoring strategies
Goyat, J., Tiwari, B. K., & Sharma, R. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33263-0.00001-2 · Cited by 2
Fernando, D. R., Senarath, U., & Katulanda, P. (2026) · Journal of Diabetology · doi:10.4103/jod.jod_147_25 · Cited by 2
QBP1 Peptide as a Potential Anti‐Amyloidogenic Therapy for Type 2 Diabetes: An In Vitro Study
Tejero-Ojeda, M. M., Vives, A. B., Wojciechowski, M., Pham, D. Q. H., Chwastyk, M., Vallejo, M., Novials, A., Laurents, D. V., & Carrión‐Vázquez, M. (2026) · Advanced Science · doi:10.1002/advs.202508344 · Cited by 3
“In type 2 diabetes (T2D), the aggregation-prone human islet amyloid polypeptide (hIAPP, or amylin) constitutes the major component of amyloid deposits in pancreatic islets [ 2, 3 ].”
Experiences of Nature Through Immersive Virtual Reality Among People with Type 2 Diabetes Mellitus
Norberg, M., Bohlin, E., Dolling, A., Krachler, B., Elfving, J., Gärdemalm, M., & Lämås, K. (2026) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph23050615 · Cited by 2
Sperlich, S., Beller, J., Epping, J., Safieddine, B., Tetzlaff, F., Tetzlaff, J., & Geyer, S. (2022) · Gesundheit und Gesellschaft · doi:10.1007/978-3-658-37692-5_10 · Cited by 2
Mohhamed, S. A., Rahimi, Z., Shakiba, E., Khadir, F., & Kohsari, M. (2022) · Avicenna Journal of Medical Biochemistry · doi:10.34172/ajmb.2022.2392 · Cited by 2
Pneumococcal vaccination in diabetic patients: review from clinical practice
Ghit, A. (2023) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-023-00202-7 · Cited by 2
Faruqui, A. A. (2023) · Journal of Medicine · doi:10.3329/jom.v24i1.64903 · Cited by 2
“It is the most common and clinically important metabolic disorder which has become a global pandemic in recent decades and a major healthcare burden worldwide 1 .”
BackgroundObradovic, M. M., Zafirovic, S. S., Gluvic, Z. M., Radovanović, J., & Isenović, E. R. (2023) · Exploration of Medicine · doi:10.37349/emed.2023.00162 · Cited by 2
Albajy, M. A., Mernea, M., Mihaila, A., Pop, C.-E., & Mihailescu, D. F. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13101466 · Cited by 3
“Obesity is a major risk factor for T2DM, the body mass index (BMI) being proportional to insulin levels and insulin resistance [4].”
BackgroundLin, Z., Zhou, X., Chen, Y., Fang, Y., Zhou, H., Wang, Z., Dang, J., & Li, G. (2024) · Molecules · doi:10.3390/molecules29020339 · Cited by 2
“Insulin resistance (IR) and dysfunction of pancreatic β -cells are factors that contribute to the progression of T2DM [4,5].”
BackgroundLoveline, L. N., & Navti, L. K. (2024) · Journal of Diabetes and Endocrinology · doi:10.5897/jde2023.0155 · Cited by 2
“T2DM is considered the largest growing global health emergency of the 21st century, with one in every five adults aged 20-79 years in the African region affected (Zheng et al., 2018; Reed et al., 2021).”
BackgroundWaititu, K., Mugo, C. W., Nyawira, D. N., & Mwethera, P. G. (2024) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2024.122013 · Cited by 2
Fabian, M. C. P., Astorga, R. M. N., Atis, A. A. G., Pilapil, L. A. E., & Hernandez, C. C. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1349725 · Cited by 2
Wu, T., Chen, L., Li, Y., & Zhang, C. (2024) · Echocardiography · doi:10.1111/echo.15913 · Cited by 3
“Some studies have shown a bidirectional association between IR and diabetes-related HF. Patients with diabetes are more likely to develop HF, and conversely, patients with HF have a high prevalence of insulin resistance in patients without T2DM and an increased risk of developing diabetes.”
InfluentialFalana, A. B., Heer, S. K., Adam, S., Adie, M., Edeani, J., Falobi, A. A., Tella, I. O., Anyanwu, G. O., Ejike, U. D., Ali, Y., et al. (2024) · Phytomedicine Plus · doi:10.1016/j.phyplu.2024.100637 · Cited by 2
Diabetes Mellitus and Neurovascular Pathology: A Comprehensive Review of Retinal and Brain Lesions
Donthula, G., & Daigavane, S. V. (2024) · Cureus · doi:10.7759/cureus.70611 · Cited by 3
“While GDM generally resolves after delivery, women with a history of GDM are at an elevated risk of developing T2D later in life [4].”
BackgroundEvaluation of Bayesian Linear Regression derived gene set test methods
Bai, Z., Gholipourshahraki, T., Shrestha, M., Hjelholt, A. J., Hu, S., Kjølby, M., Rohde, P. D., & Sørensen, P. (2024) · BMC Genomics · doi:10.1186/s12864-024-11026-2 · Cited by 2
Yarahmadi, S., Nikkhoo, B., Miraki, P., & Rahmani, K. (2025) · Journal of Health Population and Nutrition · doi:10.1186/s41043-025-00742-4 · Cited by 3
“Diabetes is a chronic metabolic disease characterized by elevated blood glucose levels, which over time, if not controlled, can lead to serious which, if not treated, leads to serious complications such as cardiovascular disorders, retinopathy, nephropathy and neuropathy [1].”
The Roles of Apolipoprotein A1-Binding Protein in Metabolic Diseases
Li, R., Tang, Y., Huang, W., Liu, J., & Liu, J. (2025) · Nutrition Reviews · doi:10.1093/nutrit/nuaf021 · Cited by 2
Peng, X., Li, S., Song, Y.-Q., Luo, Y., Liu, S., & Zhao, T. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01623-7 · Cited by 2
“…analysis must adhere to three fundamental assumptions: [ 1 ]. the genetic variants were hypothesized to be associated with Klotho concentrations; [2 ] these variants were expected to be independent of confounding variables; [3 ] their influence on diabetic nephropathy was proposed to be mediated…”
InfluentialYousuf, A. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01684-8 · Cited by 4
“Type 2 diabetes (T2D) is a rapidly escalating global health crisis that affects over 500 million people worldwide , accounting for 90–95% of all diabetes cases [1, 2].”
Jawad, A. N., Kadhim, K. A., Ali, Z. H., Fawzi, H. A., & Alzajaji, Q. B. (2025) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-025-01537-3 · Cited by 2
Huseini, H. F., Mohamadzadeh, K., Kianbakht, S., Mohammadi, S. M., Ahvazi, M., Hooseini, M. S., Khalili, N., Foroutan, B., Saberi, M., Baghaei, A., et al. (2023) · Payam Marafat Journal of Social Sciences · doi:10.61186/jmp.22.86.1 · Cited by 2
Patil, R. R., Bhise, S. B., Aswar, M. K., & Ramnath, N. S. (2023) · Revista Brasileira de Farmacognosia · doi:10.1007/s43450-023-00492-6 · Cited by 2
“This metabolic dysfunction may be due to impaired insulin secretion, action, or both (Reed et al. 2021).”
Yeung, D., Talukder, A., Shi, M., Umbach, D. M., Li, Y., Motsinger‐Reif, A. A., Fan, Z., & Li, L. (2024) · medRxiv · doi:10.1101/2024.04.11.24305676 · Cited by 2
“Diabetes mellitus is characterized by metabolic dysregulation resulting from impaired insulin secretion, insulin resistance, or a combination of both ( Bastaki 2019; DeFronzo et al. 2015; Katsarou et al. 2017; Olokoba et al. 2012; Reed et al. 2021 ).”
BackgroundAntidiabetic and Antioxidant Activity of Zanthoxylum armatum DC. on Type 2 Diabetic Rats
Kesavan, K., Hariharan, G., Sridharan, G., & Jothi, G. (2022) · International Journal of Life Science and Pharma Research · doi:10.22376/ijpbs/lpr.2022.12.3.l173-180 · Cited by 1
“It is projected that there will be >590 million patients diagnosed with this condition by 2035.(5) Changing lifestyle and food habits lead to several diseases, especially obesity, hypertension, diabetes, cardiovascular diseases, etc.”
Ragab, H. M., Maksoud, N. A. E., Amin, M. A., & Elaziz, W. A. (2023) · Beni-Suef University Journal of Basic and Applied Sciences · doi:10.1186/s43088-023-00402-8 · Cited by 1
“1 Background The most prevalent and clinically significant metabolic illness is type 2 diabetes (T2D), which has become a major global healthcare burden in recent years [1] The International Diabetes Federation (IDF) estimates that 463 million adults between the ages of 20–80 years had diabetes in 2019, and it is anti…”
BackgroundCellular lipids in the molecular pathogenesis of obesity
Matumba, M. G., Ayeleso, A. O., Ntambi, J. M., & Mukwevho, E. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95582-9.00006-1 · Cited by 1
Musafer, K. N. J., Rava, M., & Al‐Shuhaib, M. B. S. (2023) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-023-01265-6 · Cited by 2
Tyrosine nitration of glucagon impairs its function: Extending the role of heme in T2D pathogenesis
Yin, X., Ni, G., Zhang, X., Fu, S., Li, H., & Gao, Z. (2024) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2024.112519 · Cited by 1
Coşkun, S., Karakuş, B. N., Aydın, E., & Demirci, D. K. (2024) · Haliç Üniversitesi Fen Bilimleri Dergisi · doi:10.46373/hafebid.1451940 · Cited by 1
Ismail, H., Mohamed, A. I., & Islam, M. S. (2024) · Scientific African · doi:10.1016/j.sciaf.2024.e02425 · Cited by 3
Yang, J., Zhang, C.-Z., Wang, J., & Zhang, J. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i4.103567 · Cited by 1
Kuijpers, W. (2025) · Academia Nutrition and Dietetics · doi:10.20935/acadnutr7612 · Cited by 1
Gratitude Interventions in Individuals With Diabetes: An Integrative Review
Koerner, R., Valente, O., Tao, A., & Rechenberg, K. (2025) · Holistic Nursing Practice · doi:10.1097/hnp.0000000000000732 · Cited by 2
Li, Y., Ma, H., Wang, Y., Zhang, S., Zhao, Y., & Liu, Z. (2025) · Phytotherapy Research · doi:10.1002/ptr.70041 · Cited by 1
“…pancreatic beta cells (Lucier and Mathias 2024), type 2 diabetes (T2D) is mainly characterized by increased metabolic stress and inflammatory stimuli, as well as the production of high levels of fatty acids, triglycerides, and low-density lipoprotein cholesterol (Reed et al. 2021).”
Bahr, N., Nour, A. H. M., El-Kader, A. E.-K. M. A., Demellawy, M. E., & Ghareeb, D. A. (2025) · The Journal of Basic and Applied Zoology · doi:10.1186/s41936-025-00476-z · Cited by 2
“Type 2 diabetes mellitus (T2DM) is a prevalent, long-term metabolic problem (Liang et al., 2018), 382 million individuals are thought to be impacted globally, and it is anticipated that by 2035, this number will rise to 592 million (Reed et al., 2021).”
Gyebi, G. A., Rotimi, D. E., Oduba, M., Nnonyelu, I., Iyobhebhe, M. E., Salawu, M. A., Ojo, A. B., Taiwo, O. A., Olanrewaju, A. A., Oyebamiji, A. K., et al. (2025) · Food Safety and Health · doi:10.1002/fsh3.70036 · Cited by 1
“T2DM is characterized by cells becoming resistant to insulin, chronic inflammation, and various metabolic abnormalities (Reed et al. 2021).”
Sadeghi, F., Bahrami, M., Lord, B., Kaviani, M., & Mousavizadeh, S. N. (2025) · Journal of Nursing and Midwifery Sciences · doi:10.5812/jnms-164407 · Cited by 1
“The disease exerts a substantial burden not only on individuals but also on healthcare systems, economies, and societies at large (2).”
Peptides from Animal Venoms: A Promising Frontier in Diabetes Therapy via Multi-Target Mechanisms
de Almeida, J. O. C. S., Comerma-Steffensen, S., Leite, J. R. S. A., Simonsen, U., & Arcanjo, D. D. R. (2025) · Pharmaceuticals · doi:10.3390/ph18101438 · Cited by 2
“This rapid growth has led some researchers to classify diabetes as a global pandemic [2,4].”
Krishnakumar, H., Jayaraman, M., Prabhu, D., & Jeyakanthan, J. (2025) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2025.109181 · Cited by 2
Lee, H. S., Yu, Y., Kim, H., Oh, J., Park, H. R., & Kim, Y. H. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2567609 · Cited by 1
“The major risk factors for T2DM include an unhealthy diet, physical inactivity, obesity, genetic predisposition, and stress [6].”
Therapeutic Potential of Acalypha wilkesiana in Type 2 Diabetes: A Review
Inshutiyimana, S., Yesh, P. D., Aleu, M. M., Sebata, A. N., Ajumesi, K., & Norhayati, N. (2025) · Journal of Diabetes Research · doi:10.1155/jdr/6278075 · Cited by 1
Yücelbaş, C., & Yücelbaş, Ş. (2025) · Iranian Journal of Science and Technology Transactions of Electrical Engineering · doi:10.1007/s40998-025-00992-2 · Cited by 1
“…has difficulty regulating blood sugar levels, damaging organs and systems over time, resulting in reduced quality of life (Balasubramanian et al. 2020; Chen et al. 2012; Dall et al. 2016; Evren and Kucukakcali 2022 ; Griffin et al. 2000; Ma and Chan 2013; Reed et al. 2021; Sugimoto et al. 2005).”
InfluentialA Novel Murine Model for Studying Impaired Wound Healing in Diabetes
Longfield, M. S. G., Fox, S. L., Lourdesamy, J., Huang, C. X., Siwan, E., Parry, S. N., Wang, X., Boughton, P. C., Min, D., & Twigg, S. M. (2026) · International Wound Journal · doi:10.1111/iwj.70826 · Cited by 1
Lin, N., Liang, Y., Tang, M., Liu, F., Chen, L., Wu, L., Fu, Y., Li, Z., Zhu, L., & Chen, J. (2026) · Stem Cells International · doi:10.1155/sci/6616986 · Cited by 1
“Notably, around 90 % of diabetes cases are classi fi ed as Type 2 diabetes (T2D) [3].”
Islas-Islas, M., Orozco, A. M. C., Moroni-González, D., Flores-Cholula, E., Avelino-Cruz, J. E., Morales‐Medina, J. C., Díaz, A., Galindo-Ramírez, F., Treviño, S., & Vázquez‐Roque, R. A. (2026) · Metabolites · doi:10.3390/metabo16020107 · Cited by 1
Nxumalo, M. B., Khan, R. B., Ntanzi, N., Tata, F. Y., & Kumalo, H. M. (2026) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2026.102497 · Cited by 1
“Current therapeutic strategies for T2DM primarily focus on lifestyle modification combined with pharmacological interventions such as metformin, insulin secretagogues, and insulin therapy [21].”
Liu, Q., Huang, J., Pan, W., Zhuang, T., Wang, X., & Li, P. S. (2026) · Phosphorus, sulfur, and silicon and the related elements · doi:10.1080/10426507.2026.2641681 · Cited by 1
Ahmed, H. A. A., Yousef, A., Abdelwahab, S. M., Youssef, M. A., Elnozahy, S. S., Almater, R. S., Saddah, L. A. M., Al-Dhawi, M., Al-matari, N. E. N., Al-Azab, M. F. G., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-41511-5 · Cited by 1
Oroojan, A. A., etedali, H., & Lapari, H. S. (2026) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2026.103423 · Cited by 2
Lee, S. S., Kim, J. H., Bang, K., Yu, J., Kim, Y. G., Kim, S. Y., Lee, I. S., & Yoo, Y. C. (2026) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2026.2666369 · Cited by 1
“…(t2DM) and related metabolic disorders remain a growing global health challenge, with insulin resistance being a central pathological feature 1 . among the molecular mediators of insulin resistance, protein tyrosine phosphatase 1B (PtP1B) has emerged as a critical negative regulator of…”
Innovative scaffold-based strategies for diabetic wound healing: progress and prospects
Sathwara, D., Maheshwari, V., Patel, H., Dagli, K., & Joshi, D. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.126977 · Cited by 1
Nxumalo, M. B., Kumalo, H. M., Maruma, L. N., Tata, F. Y., Ntanzi, N., & Khan, R. B. (2026) · Health Sciences Review · doi:10.1016/j.hsr.2026.100274 · Cited by 3
Pancreatic α‐cell dysfunction associated with equine insulin dysregulation
Lindåse, S. S., Strage, E. M., Söder, J., & Bröjer, J. T. (2026) · Equine Veterinary Journal · doi:10.1002/evj.70322 · Cited by 1
Health Literacy and Adherence to Therapy in Type 2 Diabetes: A Cross-Sectional Study in Portugal
Rodrigues, S., Patrício, A. I., Cristina, C., Fernandes, F., Santos, G. M., Antunes, I., Pintalhão, I., Ribeiro, M., Lopes, R., Moreira, S., et al. (2024) · HLRP Health Literacy Research and Practice · doi:10.3928/24748307-20240625-01 · Cited by 1
Bactrian Camel (Camelus bactrianus) Milk Exosomes Promote Glucose Consumption in L6 Cells
Yang, B., Guo, Z., Liu, P., & Er, D. (2023) · Indian Journal of Animal Research · doi:10.18805/ijar.bf-1612 · Cited by 1
Yun, E. K., Seo, I., Lee, H. S., Seol, S., & Lee, Y. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3641 · Cited by 3
“Type 2 diabetes has emerged as a global pandemic and over 10% of adults are estimated to have type 2 diabetes worldwide by 2035.(1) Type 2 diabetes mellitus is a major cause of death and multiple comorbidities, particularly with regard to macrovascular complications such as cardiovascular diseases and stroke.”
BackgroundYadav, S. S., Roham, P. H., Roy, S., & Sharma, S. (2023) · Human Gene · doi:10.1016/j.humgen.2023.201177 · Cited by 1
Prescription of oral antidiabetics in Mexico. A cross-sectional study
Fierro, I., Gallardo-Mora, O., Alba‐Leonel, A., Carvajal, A., & Molina-Güarneros, J. (2023) · PLoS ONE · doi:10.1371/journal.pone.0288699 · Cited by 2
“Currently, it has become a global pandemic due to the increasing longevity and prevalence of contributing factors, such as obesity [1]; in 2016, diabetes was declared an epidemic and a national health emergency in Mexico [2].”
BackgroundIqbal, J., Chandio, K., Memon, A. H., Hussain, A., Talpur, R. A., & Ali, A. A. (2023) · The Professional Medical Journal · doi:10.29309/tpmj/2023.30.10.7561 · Cited by 1
Choi, Y. Y., Lyu, C., Zhang, T., Shao, H., Meng, X., Thanh, C. D., Kang, J. S., Jung, H. W., & Park, Y. (2024) · Journal of Korean Medicine for Obesity Research · doi:10.15429/jkomor.2024.24.1.25 · Cited by 1
“Type 2 diabetes (T2D) is one of the most common and clinically important metabolic disorders 1) , is characterized by chronic hyperglycemia resulting from insulin deficiency and insulin resistance 2) .”
Čypaitė, G., Diana, S. M., & Rudminaitė, E. (2024) · International Journal of Clinical Endocrinology and Metabolism · doi:10.17352/ijcem.000060
Rugera, S. P., Tumusiime, J., Mudondo, H., Naruhura, G., Kiconco, R., & Bagenda, C. N. (2024) · Cureus · doi:10.7759/cureus.69843 · Cited by 2
“It is the most common and clinically important metabolic disorder, which has become a global pandemic in recent decades and a major healthcare burden worldwide [2].”
BackgroundLee, S., Kim, S. H., Kim, S.-Y., Park, J. Y., Jung, H. S., Chung, S. S., & Park, K. S. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0174 · Cited by 1
Association of Klotho Gene Polymorphisms with Type 2 Diabetes Mellitus
Mudassar, S., Sarfraz, A., Shahid, A., Ahmed, I., Joher, I., & Anam (2025) · Pakistan Journal of Health Sciences · doi:10.54393/pjhs.v6i1.2448 · Cited by 1
Abaj, F., Mirzababaei, A., Gholizadeh, M., Aali, Y., Jadidi, P., Khosroshahi, R. A., Clark, C. C. T., & Mirzaei, K. (2025) · Journal of Health Population and Nutrition · doi:10.1186/s41043-025-00895-2 · Cited by 2
“DN is currently accountable for 31.1 percent of deaths in diabetic patients [32, 33].”
InfluentialTrzhetsynskyi, S., Носуленко, И. С., Kinichenko, A. O., Skoryna, D., Берест, Г. Г., Shvets, V., Воскобойнік, О. Ю., Коваленко, С. І., Petakh, P., & Kamyshnyi, O. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1638013 · Cited by 2
Leveraging genetic correlations to prioritize drug groups for repurposing in type 2 diabetes
Hjelholt, A. J., Gholipourshahraki, T., Bai, Z., Shrestha, M., Kjølby, M., Sørensen, P., & Rohde, P. D. (2025) · The Pharmacogenomics Journal · doi:10.1038/s41397-025-00392-z · Cited by 1
“T2D is characterized by insulin resistance and compromised insulin secretion [2], leading to chronic hyperglycaemia and complications such as cardiovascular disease, chronic kidney disease, retinopathy, and neuropathy [3, 4].”
Obtención y evaluación de matrices hidrofílicas para liberación prolongada de metformina
García‐Guzmán, P., Rodríguez, G. C., Almanza, L. O., Ramírez, M. L. V., & Aceves, L. S. (2023) · Revista Colombiana de Ciencias Químico Farmacéuticas · doi:10.15446/rcciquifa.v51n3.100434 · Cited by 1
Esquivel-Hernandez, D. A., Martínez-López, Y. E., Sánchez-Castañeda, J. P., Neri-Rosario, D., Padrón-Manrique, C., Giron-Villalobos, D., Mendoza-Ortíz, C., & Reséndis-Antonio, O. (2022) · Research Square · doi:10.21203/rs.3.rs-1848436/v1 · Cited by 1
Rovithis, M., Koukouli, S., Dimitropoulos, A., Kalaitzaki, A. E., Rikos, N., Vasilopoulos, G., Papachristou, A., Tsolas, G., Tamiolaki, A., Tsapnidou, E., et al. (2023) · Preprints.org · doi:10.20944/preprints202306.1434.v1 · Cited by 3
Yanar, A. K., & Yazıcı, Z. C. (2023) · Wiley eBooks · doi:10.1002/9781119983347.ch15 · Cited by 1
Romero, R. C. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.05.556125 · Cited by 1
“The management of T2D involves lifestyle changes such as diet and exercise, along with pharmacological prescriptions such as metformin, sulfonylureas, DPP4 inhibitors, etc., aiming to reduce blood sugar levels and improve insulin sensitivity [11, 12, 13].”
BackgroundNaeini, S. E., Bhandari, B., Rogers, H. M., Gouron, J., Chagas, P. S., Maciel, L. M., Chagas, H. I. S., Yu, J. C.-K., Seyyedi, M., Salles, É. L., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.04.597375 · Cited by 1
Metadata
- Authors
- Reed, J., Bain, S., & Kanamarlapudi, V.
- Affiliations
- Swansea University (GB)
- Corresponding author
- Reed, Josh
- Bain, Stephen
- Kanamarlapudi, Venkateswarlu
- Venue
- Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2021-08
- Volume
- Volume 14
- Pages
- 3567-3602
- ISSN
- 1178-7007 (ISSN-L)
- PMC
- PMC8369920
- OpenAlex
- W3191601669
- Cited by
- 441
- References
- 326
- Citations by year
- 2026: 73 · 2025: 109 · 2024: 107 · 2023: 98 · 2022: 51 · 2021: 2
- FWCI
- 9.88
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Diabetes Metabolic Syndrome and Obesity (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Directorate for Biological Sciences
- Medical Research Council (G0401232)
- Biotechnology and Biological Sciences Research Council (BB/S019588/1, BB/F017596/1, BB/C515455/2, 1095087)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, diabetes epidemiology, diabetes aetiology, diabetes pathogenesis, impaired insulin secretion, glucagon-like peptide-1, incretins, GLP-1 receptor agonists, bariatric surgery alternatives, weight loss, diabetes complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.